The Pathology and Tissue Informatics Core (PTIC) is essential for the success of the Vanderbilt Breast Cancer SPORE. The goal of the PTIC is to facilitate the clinical and translational research aims of this renewal application via three primary missions: 1) To provide human tissue and body fluid collection, processing and quality control according to standardized protocols by trained personnel;2) To provide specialized technical and diagnostic histo-pathology services in human and mouse tumors including expertise in performance and interpretation of immunohistochemistry (IHC), immunofluorescence (IF), and fluorescence in situ hybridization (FISH) assays, diagnostic and cellularity assessments on all procured tissue used for correlative studies, and construction of tissue microarrays;and 3) To provide high-quality and efficient informatics support for collection, pathological and clinical annotation, tracking and distribution of breast tissues for translational research. The core is co-directed by an expert breast pathologist and the Vanderbilt Ingram Cancer Center (VICC) Director of Clinical Informatics who oversees the development and maintenance of the clinical research information systems. All tissue is collected from patients with breast cancer consented for enrollment into SPORE and VICC protocols or under the auspices of the Vanderbilt Breast Tissue and Body Fluids Repository. The Repository, established in the initial funding period of this Breast SPORE, is now a robust collection of over 25,000 tissue, blood and urine samples, available to Breast SPORE investigators, which are linked to clinical data through the Breast SPORE Database. The core provides best practices oversight of optimal tissue utilization for each tissue specimen enabling numerous correlative studies such as gene arrays, sequencing and IHC to be performed on small tumor samples. The core will be directly involved in the analysis of these studies and will interact extensively with all the projects. The PTIC provides a centralized mechanism for performance of specialized technical and diagnostic histo- pathology services, critical to the success of the Breast SPORE, preventing the inefficiencies of tissue acquisition by individual projects and the performance of tissue-based assays by inexperienced hands.
The complexity of the tissue procurement process, critical nature of the sample quality assurance, intensive oversight required for optimal tissue utilization, high quality specialized technical and diagnostic histo- pathology services and the necessary informatics to efficiently support the missions of the Vanderbilt Breast Cancer SPORE justifies the need of a Pathology and Tissue Informatics core.
|Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2016) A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res :|
|Lee, Taekyu; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. FEBS Lett :|
|Harris, Leonard A; Frick, Peter L; Garbett, Shawn P et al. (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13:497-500|
|Zhao, Min; Kim, Pora; Mitra, Ramkrishna et al. (2016) TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res 44:D1023-31|
|Bhola, Neil E; Jansen, Valerie M; Koch, James P et al. (2016) Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res 76:440-52|
|Degnim, Amy C; Dupont, William D; Radisky, Derek C et al. (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122:2971-8|
|Zhao, Junfei; Cheng, Feixiong; Wang, Yuanyuan et al. (2016) Systematic Prioritization of Druggable Mutations in âˆ¼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. Mol Cell Proteomics 15:642-56|
|Pelz, Nicholas F; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. J Med Chem 59:2054-66|
|Jansen, Valerie M; Mayer, Ingrid A; Arteaga, Carlos L (2016) Is There a Future for AKT Inhibitors in the Treatment of Cancer? Clin Cancer Res 22:2599-601|
|Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23|
Showing the most recent 10 out of 304 publications